CARLSBAD, Calif., April 5, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that the U.S. Food and Drug Administration has extended its recent method equivalency finding of the Applied Biosystems TaqMan® Salmonella Enteritidis Detection Kit to test poultry eggs for additional use on environmental samples at production houses where the breakfast staple is handled and packaged. (Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO) The kit had previously received interim approval for environmental sample testing by the National Poultry Improvement Plan (NPIP), a division of the United States Department of Agriculture (USDA), which governs safety standards at poultry houses that produce animals destined for dinner tables around the world. This equivalency finding gives Life Technologies regulatory approvals for testing SE in egg and poultry houses. The latest government findings now provide egg producers and the poultry industry the market's only PCR-based (polymerase chain reaction) tool, to quickly and accurately determine the presence or absence of Salmonella Enteritidis (SE) in drag swab samples taken from production lines by directly zeroing in on the pathogen's DNA. Compared to conventional, culture-based methods of detection, the kit reduces the time to results to 27 hours versus 72 hours – roughly 10 times faster for egg samples, and three times faster for environmental drag swab samples. This kit accurately differentiates SE from other serogroup D1 Salmonella to which SE belongs. "We appreciate the work of Life Technologies to develop testing methods and tools that will provide egg farmers with rapid, reliable test results so that eggs are not withheld from the market even one day longer than necessary," said Gene Gregory, President and CEO of United Egg Producers. Preventing, rather than simply responding to, SE contaminations has become the prime focal point for the egg and poultry industries, which must now conform to stricter federal regulations outlined in the Food Safety Modernization Act (FSMA). Congress passed the FSMA in December 2010 in an effort to curtail the number of high-profile food pathogen outbreaks, the most recent of which sickened at least 2,000 people and prompted the recall of more than 500 billion eggs in the summer of 2010, according to the Associated Press. Life Technologies developed the Applied Biosystems TaqMan® Salmonella Enteritidis Detection Kit in response the Federal Egg Safety Program and launched it in January 2011 when the FDA determined that the test was equivalent in accuracy, precision and sensitivity to its current standard methods described in the federal agency's Bacteriological Analytical Manual (BAM, December 2007 Edition). Passed in July 2010, the Egg Safety Program requires all large-scale egg producers in the U.S. -- roughly 80 percent of the egg production industry -- to test for SE, and is estimated to reduce annual Salmonella-related illnesses and deaths by 60 percent, according to the FDA. "Acceptance of our detection kit for Salmonella Enteritidis by the FDA and the NPIP is in line with our strategic goal to provide the most accurate of reliable molecular tools, and to continue growing our business in this sector," said Nir Nimrodi, Vice President and General Manager of Animal Health and Food Safety. "In addition to providing a valuable testing method with dual uses, the kit can help producers easily conform to federal regulations." About Life Technologies Life Technologies Corporation is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.comLife Technologies' Safe Harbor Statement This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.